A systematic review of the gonadal effects of therapeutic radioactive iodine in male thyroid cancer survivors

Clinical Endocrinology

Volumn 68, Issue 4, 2008, Pages 610-617

  Sawka, Anna M ^a,b,k   Lea, Jane ^c   Alshehri, Bandar ^b   Straus, Sharon ^c,d   Tsang, Richard W ^a,b   Brierley, James D ^a,b   Thabane, Lehana ^e,f   Rotstein, Lorne ^a,b   Gafni, Amiram ^e,g   Ezzat, Shereen ^b,h,i,j   Goldstein, David P ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF CALGARY   (Canada)

^e MCMASTER UNIVERSITY   (Canada)

^f CENTRE FOR EVALUATION OF MEDICINES   (Canada)

^g MCMASTER UNIVERSITY   (Canada)

^h MOUNT SINAI HOSPITAL   (Canada)

ⁱ Freeman Centre for Endocrine Oncology   (Canada)

^j PRINCESS MARGARET HOSPITAL   (Canada)

^k TORONTO GENERAL HOSPITAL   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

FOLLITROPIN; LUTEINIZING HORMONE; RADIOACTIVE IODINE; TESTOSTERONE;

ARTICLE; FOLLITROPIN BLOOD LEVEL; FOLLOW UP; GONAD DYSFUNCTION; HUMAN; LONGITUDINAL STUDY; LUTEINIZING HORMONE BLOOD LEVEL; MEASUREMENT; OLIGOSPERMIA; PRIORITY JOURNAL; RISK ASSESSMENT; SYSTEMATIC REVIEW; TESTIS DISEASE; TESTOSTERONE BLOOD LEVEL; THYROID CANCER; THYROID CARCINOMA; TREATMENT OUTCOME; TUMOR DIFFERENTIATION;

FOLLICLE STIMULATING HORMONE; HUMANS; IODINE RADIOISOTOPES; LUTEINIZING HORMONE; MALE; PITUITARY GLAND; RADIATION DOSAGE; REVIEW LITERATURE AS TOPIC; SPERMATOGENESIS; TESTIS; TESTOSTERONE; THYROID NEOPLASMS; TREATMENT OUTCOME;

EID: 40749087651     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2007.03081.x     Document Type: Article

References (25)

1. Canadian Cancer Society, National Cancer Institute of Canada, Statistics Canada & Public Health Agency of Canada. Canadian Cancer Statistics 2005. Available at: http://www.cancer.ca [accessed 2 August 2005].
2. Hayat, M.J., Howlader, N., Reichman, E. Edwards, B.K. (2007) Cancer statistics, trends, and multiple primary cancers from the Surveillance, Epidemiology, and End Results (SEER) Program. Oncologist, 12, 20 37.
3. Davies, L. Welch, H.G. (2006) Epidemiology of head and neck cancer in the United States. Otolaryngology - Head and Neck Surgery, 135, 451 457.
4. Jonklaas, J., Sarlis, N.J., Litofsky, D., Ain, K.B., Bigos, T., Brierley, J.D., Cooper, D.S., Haugen, B.R., Ladenson, P.W., Magner, J., Robbins, J., Ross, D.S., Skarulis, M., Maxon, H.R. Sherman, S.I. (2006) Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid, 16, 1229 1242.
5. Hay, I.D., McConahey, W.M. Goellner, J.R. (2002) Managing patients with papillary thyroid carcinoma: insights gained from the Mayo Clinic's experience of treating 2512 consecutive patients during 1940 through 2000. Transactions of the American Clinical Climatological Association, 113, 241 260.
6. Cooper, D.S., Doherty, G.M., Haugen, B.R., Kloos, R.T., Lee, S.L., Mandel, S.J., Mazzaferri, E.L., McIver, B., Sherman, S.I. Tuttle, R.M. & the American Thyroid Association Guidelines Task Force 2006) Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid, 16, 109 142.
7. National Cancer Institute 2006) Thyroid Cancer (PDQ): Treatment. Available at: http://www.cancer.gov/cancertopics/pdq/treatment/thyroid/ healthprofessional/allpages [accessed 23 July 2006].
8. Pacini, F., Schlumberger, M., Dralle, H., Elisei, R., Smit, J.W.A. Wiersinga, W. the European Thyroid Cancer Task Force 2006) European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. European Journal of Endocrinology, 154, 787 803.
9. American Association of Clinical Endocrinologists, American College of Endocrinology & American Association of Endocrine Surgeons 2001) AACE/AAES medical/surgical guidelines for clinical practice: management of thyroid carcinoma. Endocrine Practice, 7, 202 220.
10. British Thyroid Association & Royal College of Physicians 2002) Guidelines for the Management of Thyroid Cancer in Adults. Available at: http://www.british-thyroid-association.org [accessed 23 July 2006].
11. Sawka, A.M., Thephamongkhol, K., Brouwers, M., Thabane, L., Browman, G. Gerstein, H.C. (2004) Clinical review 170: a systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. Journal of Clinical Endocrinology and Metabolism, 89, 3668 3676.
12. 131I therapy for ablation of postsurgical thyroid remnants in patients with differentiated thyroid cancer. Journal of Nuclear Medicine, 40, 1716 1721.
13. Hyer, S., Vini, L., O'Connell, M., Pratt, B. Harmer, C. (2002) Testicular dose and fertility in men following I (131) therapy for thyroid cancer. Clinical Endocrinology, 56, 755 758.
14. Krassas, G.E. Perros, P. (2003) Thyroid disease and male reproductive function. Journal of Endocrinological Investigation, 26, 372 380.
15. Altman, D.G., Machin, D., Bryant, T.N. Gardner, M.J. (2000) Statîstîcs with confidence, 2nd edn. BMJ Books, London.
16. Pacini, F., Gasperi, M., Fugazzola, L., Ceccarelli, C., Lippi, F., Centoni, R., Martino, E. Pinchera, A. (1994) Testicular function in patients with differentiated thyroid carcinoma treated with radioiodine. Journal of Nuclear Medicine, 35, 1418 1422.
17. Wichers, M., Benz, E., Palmedo, H., Biersack, H.J., Grunwald, F. Klingmuller, D. (2000) Testicular function after radioiodine therapy for thyroid carcinoma. European Journal of Nuclear Medicine, 27, 503 507.
18. Rosario, P.W., Barroso, A.L., Rezende, L.L., Padrao, E.L., Borges, M.A., Guimaraes, V.C. Purisch, S. (2006) Testicular function after radioiodine therapy in patients with thyroid cancer. Thyroid, 16, 667 670.
19. Einhorn, J., Hulten, M., Lindsten, J., Wicklund, H. Zetterqvist, P. (1972) Clinical and cytogenetic investigation in children of parents treated with radioiodine. Acta Radiologica: Therapy, Physics, Biology, 11, 193 208.
20. Esfahani, A.F., Eftekhari, M., Zenooz, N. Saghari, M. (2004) Gonadal function in patients with differentiated thyroid cancer treated with 131, I. Hellenic Journal of Nuclear Medicine, 7, 52 55.
21. Sarkar, S.D., Beierwaltes, W.H., Gill, S.P. Cowley, B.J. (1976) Subsequent fertility and birth histories of children and adolescents treated with 131I for thyroid cancer. Journal of Nuclear Medicine, 17, 460 464.
22. Dottorini, M.E., Vignati, A., Mazzucchelli, L., Lomuscio, G. Colombo, L. (1997) Differentiated thyroid carcinoma in children and adolescents: a 37-year experience in 85 patients. Journal of Nuclear Medicine, 38, 669 675.
23. Handelsman, D.J. Turtle, J.R. (1983) Testicular damage after radioactive iodine (I-131) therapy for thyroid cancer. Clinical Endocrinology, 18, 465 472.
24. Trunnel, J.B., Duffy, B.J., Godwin, J.T., Peacock, W., Kirscher, L. Hill, R. (1950) The distribution of radioactive iodine in human tissues: necropsy study in nine patients. Journal of Clinical Endocrinology and Metabolism, 10, 1007 1021.
25. Pacini, F., Ladenson, P.W., Schlumberger, M., Driedger, A., Luster, M., Kloos, R.T., Sherman, S., Haugen, B., Corone, C., Molinaro, E., Elisei, R., Ceccarelli, C., Pinchera, A., Wahl, R.L., Leboulleux, S., Ricard, M., Yoo, J., Busaidy, N.L., Delpassand, E., Hanscheid, H., Felbinger, R., Lassmann, M. Reiners, C. (2006) Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. Journal of Clinical Endocrinology and Metabolism, 91, 926 932.